Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
CellPoint has developed, in a strategic collaboration with Lonza, a novel point-of-care supply model, which offers the potential for efficient, 7-day delivery of CAR-T therapies and avoids complex logistics, thereby addressing important limitations of current CAR-T treatments.
Lead Product(s): CD19 CAR-T Cell Therapy
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Galapagos
Deal Size: $234.7 million Upfront Cash: $130.4 million
Deal Type: Acquisition June 21, 2022